Proteomics Analysis Identifies Differentially Expressed Proteins In Hep-2 Cells With Liposome Treated

More recently, cationic(positively charged) liposomes have attacked our attention as a non-viral vectors for gene therapy because of their particular characteristics, including biocompatibility, biodegradability, lack of foreign body response, and capacity to encapsulate with hydrophilic or hydrophobic drugs. Most importantly, in contrast to engineered virus vectors, liposomes have a relative safety owing to no virus gene inserted to cause disease.To gain a comprehensive differential proteomic profiles for Hep-2 cells transfected CDO14/p GFP-N2, we used two dimensional electrophoresis firstly and a 6-plex isobaric tags for relative and absolute quantification(iTRAQ) which have a high throughput and identification of low abundance proteins in complex samples. We got 1146 proteins in the treatment group which contained 58 up-regulated and 42 down-regulated. Next, a total of 4640 were identified and 3507 proteins were quantified from 19,472 unique peptides of three biological replicates, respectively by iTRAQ. After filtering, there were 258 differentially expressed proteins in the three replicates for further analysis including 146 up-regulated(>1.2 fold) and 112 down-regulated(<0.83 fold) compared with the control group(p<0.05). In this section, a variety of biological reactions were showed such as metabolic process, biological regulation, response to stimulus and immune system process by Gene Ontology Analysis. Enrichment Analysis suggested that Complement pathway was a defense system for Hep-2 cells, ECM receptor interaction pathway played an essencial role in cell migration and signal transductio n.We divided the differentially expressed proteins into four parts, such as defense, molecular chaperone, DNA replication and transcription. CDO14 has a high transfection radio and does less harm to the host cells, a promising transfection reagent has a wide range of appilaction. This work provides a basis of the influence after CDO14 treated with Hep-2 cells, gives a fundamention to design a higher and lower toxicity liposome in the future.